Per cortesia rimaniamo seri, si entra in cravatta
magiceddy
Nuovo Utente
- Registrato
- 24/6/09
- Messaggi
- 3.671
- Punti reazioni
- 77
ah bhe...
af2009
L'ANTI CRICCHE
- Registrato
- 25/9/08
- Messaggi
- 13.946
- Punti reazioni
- 149
lassalo perdere a quello...ancora mi ricordo che sul titolo Apcvz quando quotava 0.04 diceva che da li a pochi giorni andava a 0...bene dopo un paio di settimane quotava 0.14 con un rialzo a TRE cifre...e ho detto tutto
comunque pure io ho messo un cippetto su marina
petroVII
Nuovo Utente
- Registrato
- 5/3/10
- Messaggi
- 1.162
- Punti reazioni
- 23
quale SIM usate per operare in USA?
Nord kapp
Nuovo Utente
- Registrato
- 7/12/09
- Messaggi
- 3.030
- Punti reazioni
- 93
Allegati
Nord kapp
Nuovo Utente
- Registrato
- 7/12/09
- Messaggi
- 3.030
- Punti reazioni
- 93
lassalo perdere a quello...ancora mi ricordo che sul titolo Apcvz quando quotava 0.04 diceva che da li a pochi giorni andava a 0...bene dopo un paio di settimane quotava 0.14 con un rialzo a TRE cifre...e ho detto tutto
comunque pure io ho messo un cippetto su marina
Non fare il furbetto del quartiere........Parla di quanto ci stai perdendo
petroVII
Nuovo Utente
- Registrato
- 5/3/10
- Messaggi
- 1.162
- Punti reazioni
- 23
Perchè a maggio è crollata in quel modo vertiginoso?
il sembrerebbe non esiste postare la news grazie..
magiceddy
Nuovo Utente
- Registrato
- 24/6/09
- Messaggi
- 3.671
- Punti reazioni
- 77
lassalo perdere a quello...ancora mi ricordo che sul titolo Apcvz quando quotava 0.04 diceva che da li a pochi giorni andava a 0...bene dopo un paio di settimane quotava 0.14 con un rialzo a TRE cifre...e ho detto tutto
comunque pure io ho messo un cippetto su marina
tutti in Opaxio te li devi spendere i soldi
petroVII
Nuovo Utente
- Registrato
- 5/3/10
- Messaggi
- 1.162
- Punti reazioni
- 23
ari_1
150
- Registrato
- 25/10/07
- Messaggi
- 6.210
- Punti reazioni
- 186
Occhio che Cell è sulla rampa di lancio......
da anni ormai , gli ormeggi sono arrugginiti e lo start point e' pieno di rampicanti
Banana Joe
w la banana
- Registrato
- 24/4/09
- Messaggi
- 1.872
- Punti reazioni
- 64
magiceddy
Nuovo Utente
- Registrato
- 24/6/09
- Messaggi
- 3.671
- Punti reazioni
- 77
lassalo perdere a quello...ancora mi ricordo che sul titolo Apcvz quando quotava 0.04 diceva che da li a pochi giorni andava a 0...bene dopo un paio di settimane quotava 0.14 con un rialzo a TRE cifre...e ho detto tutto
comunque pure io ho messo un cippetto su marina
leggi mer.da, giusto per rimanere in tema mrna
fammi bannare, che mi faccio una settimana di ferie
http://www.finanzaonline.com/forum/28965732-post310.html
Cell Therapeutics-FDA set early June pixantrone meeting
Puget Sound Business Journal
Date: Friday, May 20, 2011, 9:52am PDT
Related: Health Care
Enlarge Image
Officials with Cell Therapeutics Inc. said they’ll meet with representatives from the U.S. Food and Drug Administration’s Office of Oncology Products early next month to discuss resubmitting the company’s pixantrone cancer drug application.
Officials with Cell Therapeutics Inc. said they’ll meet with representatives from the U.S. Food and Drug Administration’s Office of Oncology Products early next month to discuss resubmitting the company’s pixantrone cancer drug application.
Earlier this month, the FDA’s Office of New Drugs “denied the dispute appeal request to conclude that the efficacy of pixantrone has been demonstrated,” but Cell Therapeutics added the “accelerated approval of pixantrone NDA 022481 may not necessarily be out of reach based on a single controlled clinical trial, provided two key matters can be satisfactorily resolved. ... If these two key matters are addressed satisfactorily, then PIX301 could be deemed successful,” officials said in a statement.
Cell Therapeutics said it will submit a review of a research panel and additional information to the FDA.
Earlier this week, in an effort to get its stock price above the NASDAQ stock exchange’s $1-per-share minimum, Cell Therapeutics (NASDAQ: CTICD) enacted a reverse six-for-one stock split. Its shares now trade above $1 for the first time in 14 months.
Read more: Cell Therapeutics-FDA set early June pixantrone meeting | Puget Sound Business Journal
Puget Sound Business Journal
Date: Friday, May 20, 2011, 9:52am PDT
Related: Health Care
Enlarge Image
Officials with Cell Therapeutics Inc. said they’ll meet with representatives from the U.S. Food and Drug Administration’s Office of Oncology Products early next month to discuss resubmitting the company’s pixantrone cancer drug application.
Officials with Cell Therapeutics Inc. said they’ll meet with representatives from the U.S. Food and Drug Administration’s Office of Oncology Products early next month to discuss resubmitting the company’s pixantrone cancer drug application.
Earlier this month, the FDA’s Office of New Drugs “denied the dispute appeal request to conclude that the efficacy of pixantrone has been demonstrated,” but Cell Therapeutics added the “accelerated approval of pixantrone NDA 022481 may not necessarily be out of reach based on a single controlled clinical trial, provided two key matters can be satisfactorily resolved. ... If these two key matters are addressed satisfactorily, then PIX301 could be deemed successful,” officials said in a statement.
Cell Therapeutics said it will submit a review of a research panel and additional information to the FDA.
Earlier this week, in an effort to get its stock price above the NASDAQ stock exchange’s $1-per-share minimum, Cell Therapeutics (NASDAQ: CTICD) enacted a reverse six-for-one stock split. Its shares now trade above $1 for the first time in 14 months.
Read more: Cell Therapeutics-FDA set early June pixantrone meeting | Puget Sound Business Journal
FDA Sets Meeting Date in Early June to Discuss Re-submission of Pixantrone NDA for Accelerated Approval
0
0
0
SEATTLE, May 20, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTICD and MTA: CTIC) announced today that it will meet with the U.S. Food and Drugs Administration's (the "FDA") Office of Oncology Drug Products in early June to discuss the re-submission of CTI's New Drug Application ("NDA") for pixantrone for accelerated approval to treat patients with relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL"). This meeting follows CTI's receipt of the FDA's Office of New Drugs' (the "OND") response to CTI's appeal as announced on May 3, 2011, which allows CTI the opportunity to resubmit the NDA to the FDA with additional information for consideration of accelerated approval of the NDA based on the PIX 301 trial. In the FDA's response to CTI's appeal, the FDA requested that CTI submit two items—an additional review of radiographs by an independent panel and additional information regarding circumstances of stopping the clinical trial prior to achieving the planned accrual to assure reviewers that efficacy assessments were not involved in the decision to stop accrual early.
0
0
0
SEATTLE, May 20, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTICD and MTA: CTIC) announced today that it will meet with the U.S. Food and Drugs Administration's (the "FDA") Office of Oncology Drug Products in early June to discuss the re-submission of CTI's New Drug Application ("NDA") for pixantrone for accelerated approval to treat patients with relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL"). This meeting follows CTI's receipt of the FDA's Office of New Drugs' (the "OND") response to CTI's appeal as announced on May 3, 2011, which allows CTI the opportunity to resubmit the NDA to the FDA with additional information for consideration of accelerated approval of the NDA based on the PIX 301 trial. In the FDA's response to CTI's appeal, the FDA requested that CTI submit two items—an additional review of radiographs by an independent panel and additional information regarding circumstances of stopping the clinical trial prior to achieving the planned accrual to assure reviewers that efficacy assessments were not involved in the decision to stop accrual early.